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Chronic infection with Pseudomonas aeruginosa (Pa) in patients with Cystic Fibro-
sis (CF) is associated with increased morbidity and mortality. Respiratory muscle
function can be assessed by maximal inspiratory pressure (Pimax), maximal expira-
tory pressure (Pemax) and pressure-time index of the respiratory muscles (PTImus).
Objectives: To compare respiratory muscle function by measurement of Pimax,
Pemax and PTImus between CF patients at different stages of Pa infection in a large
cohort comprising of children and young adults.
Methods:We investigated the differences in maximal respiratory pressures, PTImus
and anthropometric indices in different stages of Pa infection according to the Leeds
criteria (never infected, free of infection, intermittent infection, chronic infection).
FEV1, FVC, MEF25−75, Body Mass Index, Upper Arm Muscle Area (UAMA),
Pimax, Pemax and PTImus were assessed in 122 CF patients who formed four groups
matched for age and gender according to the different stages of Pa infection.
Results: Median Pimax was signiﬁcantly lower in CF patients with chronic Pa
infection compared to patients that were never infected, free of infection or inter-
mittently infected. Median PTImus was signiﬁcantly increased in CF patients with
chronic Pa infection compared to patients that were free of infection. Multivariate
logistic regression revealed state of infection as a signiﬁcant determinant of PTImus
independently of UAMA and FEV1.
Conclusion: CF patients with chronic Pa infection exhibit impaired respiratory
muscle function and decreased inspiratory muscle strength. Chronic Pa infection
might independently impact on respiratory muscle function in patients with CF.
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Objectives: P. aeruginosa is the primary cause for pulmonary destruction and
premature death in CF patients. Therefore it is of highest interest to prevent airway
colonization with the pathogen that is ubiquitously present in water. Whereas it is
frequently detected in dental unit waterlines with proven transmission to CF patients,
risks of acquisition within otorhinolaryngological treatment have not yet been
discussed, although some perils could be comparable.
We present ﬁve CF patients who primarily acquired P. aeruginosa around otorhi-
nolaryngological surgery (4) or dentist treatment (1). Additionally, we discuss risks
and preventive strategies for CF patients undergoing otorhinological treatment.
Altogether, risks range from contact to pathogen carriers in waiting rooms to
instrumentation, suction, drilling or ﬂushing ﬂuid in oral and sinonasal areas, when
droplets containing pathogens can be nebulized into CF airways. Postsurgically
mucosal damage impairs sinonasal mucociliary clearance, which additionally to
debridement and crusts facilitates pathogens to clinch and proliferate.
Thus, otorhinolaryngological surgery in CF must be linked to repeated assessment
of pathogen colonization, together with cleansing, anti-inﬂammatory and antibiotic
therapy. Further studies must elaborate, whether all operated CF patients, indepen-
dent from pre-surgical colonization status, would routinely require antipseudomonal
treatment, including nasal lavages containing antibiotics as presented in a series of
protocols. Altogether, we must bring up attention on this probably underestimated
risk within CF therapy and postulate structured prevention protocols, available to
all patients.
184 Determinants of nontuberculous mycobacteria eradication in
cystic ﬁbrosis
L. Coupet1, A. Prevotat2, S. Dominique3, G. Rault4, R. Chiron5, I. Sermet6,
P. Domblides7, M. Murris8, S. Bui7, D. Grenet9, C. Langlois10, B. Wallaert1.
1Hoˆpital Calmette, Service de Pneumologie, Lille, France; 2Hoˆpital Calmette,
Lille, France; 3Rouen University Hospital, Rouen, France; 4Centre de Perihardy,
Roscoff, France; 5Hoˆpital de Montpellier, Montpellier, France; 6Hoˆpital Necker,
Paris, France; 7CHU de Bordeaux, Bordeaux, France; 8Hoˆpital Larrey, Toulouse,
France; 9Hoˆpital Foch, Suresnes, France; 10CHRU Lille, Lille, France
Objectives: The prevalence of colonization with nontuberculous mycobacteria
(NTM) in cystic ﬁbrosis (CF) is increasing. The aim of this retrospective, mul-
ticenter study was to characterize the factors associated with NTM eradication in
infected or colonized CF patients.
Methods: All CF patients in whom NTM had been identiﬁed in at least two sputum
cultures were included. The infection caused by NTM was considered as a disease
when CF clinicians decided the appropriate therapeutic management. Univariate
and multivariate analyses were performed to identify risk factors.
Results: Fifty patients were included. The most frequently identiﬁed NTM wereMy-
cobacterium abscessus (56%) and Mycobacterium avium complex (34%). Twenty-
eight patients were infected and treated; 22 patients were colonized. The decline in
FEV1 between the time of NTM identiﬁcation and two years later was higher in
infected-treated than in colonized patients. The presence of Aspergillus fumigatus
in sputum was associated with NTM infection. The previous administration of
azithromycin and/or PPIs was associated with microbiological cure, regardless of
the type of therapeutic management.
Conclusion: Our results suggest that the identiﬁcation of Aspergillus fumigatus in
patients with CF should particularly lead to suspect NTM lung disease. Previous
azithromycin treatment did not prevent NTM eradication or could have a primary
prophylactic effect and promote microbiological cure. A better assessment of NTM
infection and a better knowledge of the predictive criteria of eradication should
improve the management of CF patients.
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Objectives: Chronic airway infections are a major cause of morbidity and mortality
in patients with CF. The role of bacteria in acute bronchopulmonary exacerbation
events is well known. Cases describing fungal involvement in pulmonary infections
are known for ABPA and in patients who are immunocompromised, such as lung
transplant recipients. Invasive pulmonary mycosis in immunocompetent CF patients
has rarely been described. Diagnostic procedures and treatment guidelines are
missing.
Methods: In this study, from 12 CF centers in Germany 17 out of approximately
1200 patients with a high suspicion of an infection with a Scedosporium or
Pseudallescheria spp. were evaluated. Criteria for invasive fungal infection were the
following: increased sputum production, multiple pathogen detection in sputum or
lavage samples, new pulmonary inﬁltrates, treatment failure with antibiotic therapy,
unclear FEV1 decrease and speciﬁc antibody detection. Sputum and lavage samples
were cultivated on SceSel + agar. Isolates were identiﬁed by sequencing of the ITS
reagions of ribosomal DNA genes, antifungal susceptibility testing was performed
using the microdilution reference method CSLI.
Conclusion: Pulmonary infection by Scedosporium or Pseudallescheria spp. can
also occur in immunocompetent patients with CF. For microbiological detection of
fungi, ScelSel + agar or an adequate selective culture medium may be usefull. To
conﬁrm an invasive fungal infection, the detection of speciﬁc antibodies can be
helpful. The therapy should be done with two systemic and one inhaled antifungal
drug for at least 4 weeks. In some cases a much longer therapy is required.
